• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
10 Truveta Research insights & publications of 2023

10 Truveta Research insights & publications of 2023

by Truveta staff | Dec 15, 2023 | Research

As 2023 draws to a close and we reflect on a busy and exciting year for Truveta, something that stands out is the breadth and depth of research Truveta Research has been able to produce using Truveta Data and Truveta Studio. From studying new Alzheimer’s disease...
First real-world comparative effectiveness study finds tirzepatide (Mounjaro) up to three times more effective than semaglutide (Ozempic) for weight loss

First real-world comparative effectiveness study finds tirzepatide (Mounjaro) up to three times more effective than semaglutide (Ozempic) for weight loss

by Truveta Research | Nov 27, 2023 | Research, Research Insights

In the first comparative effectiveness study of tirzepatide (Mounjaro) and semaglutide (Ozempic) for weight loss using real-world data, Truveta Research found that patients with overweight or obesity taking tirzepatide were three times more likely to achieve 15%...
Ozempic, Wegovy, and Mounjaro: On- and off-label prescribing trends

Ozempic, Wegovy, and Mounjaro: On- and off-label prescribing trends

by Truveta Research | Jun 6, 2023 | Research, Research Insights

Beginning in Fall 2022, the news media has reported extensively on the use of Glucagon-like peptide-1 receptor agonist (GLP-1s) for weight loss (Belluz, 2023). Physicians have taken to TikTok to promote GLP-1s for weight loss, and celebrities & influencers – such...
Next Entries »

Share this


Recent posts

  • One-year cardiovascular outcomes after GLP-1 discontinuation
  • Truveta experts: Biomarker testing trends in metastatic non-small cell lung cancer (NSCLC)
  • Multiple sclerosis: Real-world treatment patterns and outcomes

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Our website uses cookies to ensure you have the best experience.